RMED VS XBIO Stock Comparison

Performance

RMED
10/100

RMED returned -95.79% in the last 12 months. Based on SPY's performance of -8.73%, its performance is below average giving it a score of 10 of 100.

XBIO
10/100

XBIO returned -23.17% in the last 12 months. Based on SPY's performance of 448.66%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

RMED
75/100

4 analysts offer 12-month price targets for RMED. Together, they have an average target of 0, the most optimistic target put RMED at 0 within 12-months and the most pessimistic has RMED at 0. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

XBIO
100/100

1 analysts offer 12-month price targets for XBIO. Together, they have an average target of 0, the most optimistic target put XBIO at 0 within 12-months and the most pessimistic has XBIO at 0.

Technicals

RMED
11/100

RMED receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

XBIO
39/100

XBIO receives a 39 of 100 based on 14 indicators. 5 are bullish, 8 are bearish.

Earnings

RMED
10/100

RMED has missed earnings 12 times in the last 20 quarters.

XBIO
10/100

XBIO has missed earnings 7 times in the last 20 quarters.

Profit

RMED
10/100

Out of the last 20 quarters, RMED has had 0 profitable quarters and has increased their profits year over year on 0 of them.

XBIO
10/100

Out of the last 20 quarters, XBIO has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

RMED
44/100

RMED has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

XBIO
38/100

XBIO has had a lower than average amount of volatility over the last 12 months giving it a score of 38 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Ra Medical Systems, Inc Summary

Healthcare

Medical Devices

Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. The company sells its products primarily through distributors in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.

Xenetic Biosciences, Inc. Summary

Nasdaq / XBIO

Healthcare

Biotechnology

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Power up your portfolio